Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report: Table 1

David Maahs , Bruce Buckingham , Jessica Castle , Ali Cinar , Edward Damiano , Eyal Dassau , J. Hans Devries , Francis Doyle , Steven Griffen , Ahmad Haidar , Lutz Heinemann , Roman Hovorka , Timothy Jones , Craig Kollman , Boris Kovatchev , Brian Levy , Revital Nimri , David O'Neal , Moshe Philip , Eric Renard (1, 2, 3) , Steven Russell , Stuart Weinzimer , Howard Zisser , John Lum

1 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
2 CIC Montpellier
3 IGF - Institut de Génomique Fonctionnelle

Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with the wider AP community 1) advocate for the use of continuous glucose monitoring glucose metrics as outcome measures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes.

Domaines: Endocrinologie et métabolisme

David Maahs, Bruce Buckingham, Jessica Castle, Ali Cinar, Edward Damiano, et al.. Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report: Table 1. Diabetes Care, 2016, 39 (7), pp.1175 - 1179. ⟨10.2337/dc15-2716⟩. ⟨hal-01865047⟩